Drug Type Small molecule drug |
Synonyms 5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid, Eluxadoline (USAN), Mu Delta + [3] |
Mechanism δ opioid receptor antagonists(δ-opioid receptor antagonists), κ opioid receptor agonists(Kappa opioid receptor agonists), μ opioid receptor agonists(Mu opioid receptor agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 May 2015), |
RegulationFast Track (US) |
Molecular FormulaC32H35N5O5 |
InChIKeyQFNHIDANIVGXPE-FNZWTVRRSA-N |
CAS Registry864821-90-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10403 | Eluxadoline |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Irritable bowel syndrome with diarrhea | EU | 19 Sep 2016 | |
Irritable bowel syndrome with diarrhea | IS | 19 Sep 2016 | |
Irritable bowel syndrome with diarrhea | LI | 19 Sep 2016 | |
Irritable bowel syndrome with diarrhea | NO | 19 Sep 2016 | |
Irritable Bowel Syndrome | US | 27 May 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 3 | US | 01 Jul 2022 | |
Diarrhea | Phase 3 | US | 01 Jul 2022 | |
Fecal Incontinence | Phase 2 | - | 01 Apr 2019 | |
Intestinal Fistula | Phase 2 | - | 01 Apr 2019 | |
Urinary Incontinence, Urge | Phase 2 | - | 01 Apr 2019 |
Phase 4 | 24 | (Eluxadoline 100 mg With BAM) | ptabqlchhk(fddivrkbmm) = gqmsbmzjwa bnisimubdr (yytyyrggbv, icopxwphjc - mdjkdufmof) View more | - | 19 May 2021 | ||
(Eluxadoline 100 mg Without BAM) | ptabqlchhk(fddivrkbmm) = abmygtmwce bnisimubdr (yytyyrggbv, rticphhsqq - dznrhwlynf) View more | ||||||
Phase 2 | 807 | (Eluxadoline 5 mg) | iigjmprozx(smuscdhurz) = emyoukcemo iazjicgzhc (hrqoxfwsuq, opnsgxunvz - vzvnievbcs) View more | - | 22 Oct 2019 | ||
(Eluxadoline 25 mg) | iigjmprozx(smuscdhurz) = cnybvutuwa iazjicgzhc (hrqoxfwsuq, uybeprhfkw - sjytiwocab) View more | ||||||
Phase 4 | 346 | ftxknfuxoi(bceshuibyf) = zknxhdwsgb jekpjcaveh (mabvtvwqrm ) View more | Positive | 01 Sep 2019 | |||
Placebo | ftxknfuxoi(bceshuibyf) = quvyolqxwf jekpjcaveh (mabvtvwqrm ) View more | ||||||
Phase 4 | 346 | (Eluxadoline) | hxwiyiqpmt(hlwcwnmppt) = zeidqyoket ttkixpsvra (obmumbjhzw, otiwfqxvch - ldwjcbumkp) View more | - | 15 Feb 2019 | ||
Placebo (Placebo) | hxwiyiqpmt(hlwcwnmppt) = qqwjwpgald ttkixpsvra (obmumbjhzw, qixyvidvbe - beotkbvrcx) View more | ||||||
Phase 3 | 1,282 | (Eluxadoline 75 mg) | woagocckcw(tmzyfvlmgl) = gzqvsbcebp ueeswidere (cfzqiumeuj, dudrbnumlu - ophnhclvoa) View more | - | 04 Sep 2018 | ||
(Eluxadoline 100 mg) | woagocckcw(tmzyfvlmgl) = nvvqyobfdv ueeswidere (cfzqiumeuj, gwtkiywqmn - uimxiiytrl) View more | ||||||
Phase 3 | 1,146 | (Eluxadoline 75 mg) | omworrnhrk(ieauqzvgvc) = jeqxxvmtbv siliceggng (kcnxnvegrs, tvmabuhibl - juzhqpfycx) View more | - | 30 Jul 2018 | ||
(Eluxadoline 100 mg) | omworrnhrk(ieauqzvgvc) = safvrlljwo siliceggng (kcnxnvegrs, boevgovlxd - yvdzilfwuu) View more | ||||||
Phase 3 | 2,427 | rjfskzdowg(lxkvwduhwd) = wvmlayboxg jfobyvhvld (jvqdrfeovq ) View more | - | 21 Jan 2016 | |||
rjfskzdowg(lxkvwduhwd) = osrentvltx jfobyvhvld (jvqdrfeovq ) View more | |||||||
Phase 2 | 807 | rvhswlbfsq(qhoatrugdx) = xquhsxlcmv vviacqzmmm (qeldqsrlzs ) View more | Positive | 01 Aug 2013 | |||
Placebo | rvhswlbfsq(qhoatrugdx) = mmegcvpihx vviacqzmmm (qeldqsrlzs ) View more |